Skip to main content
. Author manuscript; available in PMC: 2011 Feb 1.
Published in final edited form as: J Drug Target. 2010 Feb;18(2):115–124. doi: 10.3109/10611860903244181

Figure 2.

Figure 2

Clone screening of their binding to live human breast cancer cells. Randomly selected 58 clones following panning were screened for their binding to live MDA-MB-361 cells. The human non-cancer MCF 10A epithelial cells and mouse fibroblast 3T3 cell-line were used as negative control cells. The screening was based on assaying the cell-bound β-lactamase activities. The clones expressing wild-type β-lactamase (Wt-BLA; without fusion peptide) and unselected library were used as negative clone controls. The bars represent β-lactamase activity as change in relative fluorescence unit (RFU)/min ± SE. *p≤0.05, significance of difference in the binding of clones to MDA-MB-361 cells in comparison to MCF 10A or 3T3 cells were determined using Student's T-test.